Home / IPHYF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does IPHYF make money? Does IPHYF have pricing power? What's the Earnings Whisper? Will IPHYF profit more as the business scales? What is IPHYF's management track record? Is IPHYF's current price justified?

Innate Pharma S.A.

$1.65 -$0.50 (-23.26%)

OTC · 14 Sep 2026 20:00 UTC

Previous Close

$1.65

Day Range

$1.65$2.25

Year Range

$1.37$2.25

Market Cap

154.94M

AVG Volume

111

Trailing/Forward PE

-2.8/-

PEG ratio

-0.08

Dividend Yield

Next Earnings Date

2026-09-17

Primary Exchange

Other OTC

Revenue (EUR)

IPHYF Revenue (EUR) by quarter
Period	Revenue (EUR)
25 Q4	1.12M
25 Q2	4.86M
24 Q4	276K
24 Q2	12.35M
23 Q4	21.44M
23 Q2	40.2M
22 Q4	8.31M
22 Q2	41.27M
21 Q4	2.79M
21 Q2	9.32M

Net Income (EUR)

IPHYF Net Income (EUR) by quarter
Period	Net Income (EUR)
25 Q4	-27.82M
25 Q2	-21.34M
24 Q4	-24.71M
24 Q2	-24.76M
23 Q4	-9.29M
23 Q2	1.72M
22 Q4	-64.41M
22 Q2	6.3M
21 Q4	-29.09M
21 Q2	-23.72M

Operating Income (EUR)

IPHYF Operating Income (EUR) by quarter
Period	Operating Income (EUR)
25 Q4	-28M
25 Q2	-25.43M
24 Q4	-25.26M
24 Q2	-26.31M
23 Q4	-12.27M
23 Q2	-398K
22 Q4	-28.8M
22 Q2	4.17M
21 Q4	-30.9M
21 Q2	-26.58M

EBITDA (EUR)

IPHYF EBITDA (EUR) by quarter
Period	EBITDA (EUR)
25 Q4	-18.59M
25 Q2	-25.06M
24 Q4	-21.35M
24 Q2	-25.56M
23 Q4	-10.4M
23 Q2	2.82M
22 Q4	-10.08M
22 Q2	6.22M
21 Q4	-12.16M
21 Q2	-8.08M

Cash Flows (EUR)

IPHYF Cash Flows (EUR) by quarter
Period	Cash Flows (EUR)
25 Q4	-21.66M
25 Q2	-31.22M
24 Q4	-10.04M
24 Q2	2.75M
23 Q4	-21.14M
23 Q2	-11.78M
22 Q4	-20.91M
22 Q2	628K
21 Q4	-28.16M
21 Q2	-31.57M

EPS (EUR)

IPHYF EPS (EUR) by quarter
Period	EPS (EUR)
25 Q4	-0.3
25 Q2	-0.25
24 Q4	-0.3
24 Q2	-0.31
23 Q4	-0.12
23 Q2	0.02
22 Q4	-0.8
22 Q2	0.08
21 Q4	-0.37
21 Q2	-0.3

Expenses (EUR)

IPHYF Expenses (EUR) by quarter
Period	Expenses (EUR)
25 Q4	24.41M
25 Q2	30.34M
24 Q4	25.36M
24 Q2	38.94M
23 Q4	33.76M
23 Q2	40.91M
22 Q4	35.43M
22 Q2	35.48M
21 Q4	32.31M
21 Q2	34.04M

Cash & Debt (EUR)

IPHYF Cash & Debt (EUR) by quarter
Period	Cash & Debt (EUR)
25 Q4	34.3M
25 Q2	60.03M
24 Q4	80.77M
24 Q2	91.8M
23 Q4	92.46M
23 Q2	88.89M
22 Q4	101.48M
22 Q2	123.35M
21 Q4	119.84M
21 Q2	119.32M

Debt ratios

IPHYF Debt ratios by quarter
Period	Debt ratios
25 Q4	0.13
25 Q2	0.4
24 Q4	0.91
24 Q2	1.3
23 Q4	4.6
23 Q2	3.65
22 Q4	2.46
22 Q2	-11.31
21 Q4	-2042.84
21 Q2	-3.19

Margins

IPHYF Margins by quarter
Period	Margins
25 Q4	39.34%
25 Q2	-322.22%
24 Q4	10634.78%
24 Q2	-135.53%
23 Q4	-14.58%
23 Q2	21.75%
22 Q4	-60.71%
22 Q2	69.77%
21 Q4	-361.8%
21 Q2	-13.79%

Return on Capital

IPHYF Return on Capital by quarter
Period	Return on Capital
25 Q4	128.24%
25 Q2	-414.93%
24 Q4	-279.68%
24 Q2	-86%
23 Q4	-17.9%
23 Q2	2.97%
22 Q4	-118.94%
22 Q2	5.42%
21 Q4	-27.08%
21 Q2	-17.76%

Shares Outstanding

IPHYF Shares Outstanding by quarter
Period	Shares Outstanding
25 Q4	91.41M
25 Q2	85.38M
24 Q4	81.05M
24 Q2	79.88M
23 Q4	80.59M
23 Q2	85.9M
22 Q4	80.19M
22 Q2	79.74M
21 Q4	79.54M
21 Q2	79M

Book Value Per Share (EUR)

IPHYF Book Value Per Share (EUR) by quarter
Period	Book Value Per Share (EUR)
25 Q4	-0.24
25 Q2	0.06
24 Q4	0.11
24 Q2	0.36
23 Q4	0.64
23 Q2	0.67
22 Q4	0.68
22 Q2	1.46
21 Q4	1.35
21 Q2	1.69

Total Assets (EUR)

IPHYF Total Assets (EUR) by quarter
Period	Total Assets (EUR)
25 Q4	62.7M
25 Q2	92.94M
24 Q4	111.06M
24 Q2	151.5M
23 Q4	175.19M
23 Q2	199.05M
22 Q4	207.86M
22 Q2	280.43M
21 Q4	267.5M
21 Q2	266.22M

Employee Count

IPHYF Employee Count by quarter
Period	Employee Count
2025	164
2024	181
2023	179
2022	211
2021	215
2020	245
2019	235

Free Cash Flow Yield

IPHYF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-46.29%
Sep 26	-46.29%
Sep 26	-46.36%
Aug 26	-46.23%
Aug 26	-46.6%
Aug 26	-46.16%
Aug 26	-46.12%
Jul 26	-46.01%
Jul 26	-45.38%
Jul 26	-45.65%
Jul 26	-45.56%
Jul 26	-45.63%
Jun 26	-45.43%
Jun 26	-45.74%
Jun 26	-46.17%
Jun 26	-45.98%
May 26	-46.51%
May 26	-33.95%
May 26	-34.03%
May 26	-51.74%
May 26	-51.45%
Apr 26	-51.46%
Apr 26	-51.64%
Apr 26	-56.36%
Apr 26	-55.48%
Mar 26	-55.32%
Mar 26	-37.6%
Mar 26	-37.17%
Mar 26	-37.76%
Feb 26	-38.43%
Feb 26	-38.29%
Feb 26	-38.58%
Feb 26	-38.4%
Jan 26	-38.51%
Jan 26	-38.44%
Jan 26	-37.7%
Jan 26	-37.82%
Jan 26	-38.09%
Dec 25	-38.26%
Dec 25	-38.05%
Dec 25	-43.18%
Dec 25	-40.88%
Nov 25	-40.52%
Nov 25	-40.22%
Nov 25	-40.6%
Nov 25	-40.4%
Oct 25	-40.45%
Oct 25	-40.63%
Oct 25	-40.71%
Oct 25	-40.62%
Oct 25	-41.03%
Sep 25	-40.88%
Sep 25	-41.03%
Sep 25	-29.09%
Sep 25	-28.22%
Aug 25	-28.14%
Aug 25	-28.23%
Aug 25	-28.19%
Aug 25	-44.08%
Aug 25	-43.87%
Jul 25	-44.45%
Jul 25	-44.01%
Jul 25	-44.26%
Jul 25	-29.91%
Jun 25	-29.8%
Jun 25	-32.85%
Jun 25	-32.93%
Jun 25	-38.98%
May 25	-38.83%
May 25	-38.89%
May 25	-38.19%
May 25	-38.48%
May 25	-38.65%
Apr 25	-50.12%
Apr 25	-50.14%
Apr 25	-50.11%
Apr 25	-24.17%
Mar 25	-23.9%
Mar 25	-23.85%
Mar 25	-24.01%
Mar 25	-23.88%
Feb 25	-22.87%
Feb 25	-23.07%
Feb 25	-23.13%
Feb 25	-22.77%
Jan 25	-22.84%
Jan 25	-23.13%
Jan 25	-22.64%
Jan 25	-22.59%
Jan 25	-22.73%
Dec 24	-22.98%
Dec 24	-22.99%
Dec 24	-23.16%
Dec 24	-52.78%
Nov 24	-52.83%
Nov 24	-52.05%
Nov 24	-52.65%
Nov 24	-30.59%
Nov 24	-30.94%
Oct 24	-30.82%

Price to Sales

IPHYF Price to Sales by quarter
Period	Price to Sales
Sep 26	6.99
Sep 26	6.99
Sep 26	6.98
Aug 26	7
Aug 26	6.94
Aug 26	7.01
Aug 26	7.02
Jul 26	7.03
Jul 26	7.13
Jul 26	7.09
Jul 26	7.1
Jul 26	7.09
Jun 26	7.12
Jun 26	7.07
Jun 26	7.01
Jun 26	7.04
May 26	6.96
May 26	9.53
May 26	9.51
May 26	6.25
May 26	6.29
Apr 26	6.29
Apr 26	6.27
Apr 26	5.74
Apr 26	5.83
Mar 26	5.85
Mar 26	4.07
Mar 26	4.12
Mar 26	4.06
Feb 26	3.99
Feb 26	4
Feb 26	3.97
Feb 26	3.99
Jan 26	3.98
Jan 26	3.99
Jan 26	4.06
Jan 26	4.05
Jan 26	4.02
Dec 25	4.01
Dec 25	4.03
Dec 25	3.55
Dec 25	3.75
Nov 25	3.78
Nov 25	3.81
Nov 25	3.77
Nov 25	3.79
Oct 25	3.79
Oct 25	3.77
Oct 25	3.76
Oct 25	3.77
Oct 25	3.73
Sep 25	3.75
Sep 25	3.73
Sep 25	1.86
Sep 25	1.92
Aug 25	1.92
Aug 25	1.92
Aug 25	1.92
Aug 25	1.23
Aug 25	1.23
Jul 25	1.22
Jul 25	1.23
Jul 25	1.22
Jul 25	1.81
Jun 25	1.82
Jun 25	1.65
Jun 25	1.64
Jun 25	1.39
May 25	1.39
May 25	1.39
May 25	1.42
May 25	1.41
May 25	1.4
Apr 25	1.24
Apr 25	1.24
Apr 25	1.24
Apr 25	2.57
Mar 25	2.6
Mar 25	2.6
Mar 25	2.58
Mar 25	2.6
Feb 25	2.71
Feb 25	2.69
Feb 25	2.68
Feb 25	2.72
Jan 25	2.72
Jan 25	2.68
Jan 25	2.74
Jan 25	2.75
Jan 25	2.73
Dec 24	2.7
Dec 24	2.7
Dec 24	2.68
Dec 24	1.18
Nov 24	1.17
Nov 24	1.19
Nov 24	1.18
Nov 24	2.03
Nov 24	2.01
Oct 24	2.01

EV/EBITDA

IPHYF EV/EBITDA by quarter
Period	EV/EBITDA
Mar 23	16.87
Mar 23	17.09
Mar 23	21.56
Mar 23	21.66
Mar 23	19.86
Feb 23	20.13
Feb 23	24.96
Feb 23	25.02
Feb 23	24.63
Jan 23	24.38
Jan 23	25.26
Jan 23	24.81
Jan 23	23.33
Dec 22	23.13
Dec 22	16.84
Dec 22	12.03
Dec 22	12.77
Dec 22	13.51
Nov 22	13.51
Nov 22	13.7
Nov 22	11.34
Nov 22	12.23
Oct 22	12.33
Oct 22	12.58
Oct 22	12.69
Oct 22	11.03
Sep 22	10.9
Sep 22	18.6
Sep 22	17.96
Sep 22	3263.08
Sep 22	3401.21
Aug 22	4079.69
Aug 22	3951.32
Aug 22	3782.4
Aug 22	3826.03
Jul 22	4598.36
Jul 22	3636.83
Jul 22	3712.87
Jul 22	3445.47
Jul 22	3318.59
Jun 22	3250.96
Jun 22	2604.43
Jun 22	3613.77
Jun 22	4112.88
May 22	3624.35
May 22	3718.65
May 22	3798.35
May 22	3598.88
Apr 22	3561.1
Apr 22	4008.28
Apr 22	4011.8
Apr 22	4814.22
Apr 22	4.5
Mar 22	4.85
Mar 22	4.8
Mar 22	4.91
Mar 22	4.89
Feb 22	4.65
Feb 22	4.62
Feb 22	4.73
Feb 22	5.58
Jan 22	5.09
Jan 22	5.98
Jan 22	6.14
Jan 22	6.18
Dec 21	6.18
Dec 21	7.64
Dec 21	7.92
Dec 21	7.34
Dec 21	6.39
Nov 21	7.24
Nov 21	7.86
Nov 21	8.04
Nov 21	8.87
Oct 21	8.8
Oct 21	8.9
Oct 21	9.26
Oct 21	9.61
Oct 21	9.47
Sep 21	10.84
Sep 21	13.25
Sep 21	5.34
Sep 21	6.41
Aug 21	1.99
Aug 21	1.75
Aug 21	1.57
Aug 21	1.49
Jul 21	1.46
Jul 21	1.49
Jul 21	1.6
Jul 21	1.77
Jul 21	2.24
Jun 21	1.76
Jun 21	2.21
Jun 21	1.87
Jun 21	1.98
May 21	2.14
May 21	2.15
May 21	2.16
May 21	2.54

Price/Operating Cashflow

IPHYF Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Sep 20	103.65
Aug 20	99.76
Aug 20	104.02
Aug 20	102.73
Aug 20	99.65
Jul 20	101.52
Jul 20	102.54
Jul 20	104.6
Jul 20	105.78
Jul 20	101.8
Jun 20	114.45
Jun 20	107.26
Jun 20	106.54
Jun 20	104.21
May 20	105.91
May 20	122.44
May 20	123.39
May 20	118.45
May 20	112.71
Apr 20	116.88
Apr 20	103.51
Apr 20	91.34
Apr 20	92.25
Mar 20	89.55
Mar 20	71.88
Mar 20	102.05
Mar 20	129.3
Feb 20	135.45
Feb 20	145.22
Feb 20	144.33
Feb 20	134.49
Jan 20	137.59
Jan 20	138.43
Jan 20	139.49
Jan 20	133.27
Jan 20	137.71

Price to Book

IPHYF Price to Book by quarter
Period	Price to Book
Mar 26	30.83
Mar 26	31.19
Mar 26	30.71
Feb 26	30.17
Feb 26	30.28
Feb 26	30.06
Feb 26	30.2
Jan 26	30.11
Jan 26	30.16
Jan 26	30.76
Jan 26	30.66
Jan 26	30.44
Dec 25	30.31
Dec 25	30.47
Dec 25	26.86
Dec 25	28.36
Nov 25	28.62
Nov 25	28.83
Nov 25	28.56
Nov 25	28.7
Oct 25	28.66
Oct 25	28.54
Oct 25	28.48
Oct 25	28.54
Oct 25	28.26
Sep 25	28.36
Sep 25	28.26
Sep 25	15.64
Sep 25	16.12
Aug 25	16.17
Aug 25	16.12
Aug 25	16.14
Aug 25	10.32
Aug 25	10.37
Jul 25	10.24
Jul 25	10.34
Jul 25	10.28
Jul 25	15.21
Jun 25	15.27
Jun 25	13.85
Jun 25	13.82
Jun 25	11.67
May 25	11.72
May 25	11.7
May 25	11.91
May 25	11.83
May 25	11.77
Apr 25	3.54
Apr 25	3.54
Apr 25	3.54
Apr 25	7.34
Mar 25	7.42
Mar 25	7.44
Mar 25	7.38
Mar 25	7.42
Feb 25	7.75
Feb 25	7.69
Feb 25	7.67
Feb 25	7.79
Jan 25	7.77
Jan 25	7.67
Jan 25	7.83
Jan 25	7.85
Jan 25	7.8
Dec 24	7.72
Dec 24	7.71
Dec 24	7.66
Dec 24	3.36
Nov 24	3.36
Nov 24	3.41
Nov 24	3.37
Nov 24	5.8
Nov 24	5.73
Oct 24	5.75
Oct 24	5.72
Oct 24	5.68
Oct 24	5.66
Sep 24	5.57
Sep 24	5.47
Sep 24	5.76
Sep 24	3.22
Aug 24	3.23
Aug 24	3.19
Aug 24	2.96
Aug 24	2.99
Aug 24	2.75
Jul 24	2.76
Jul 24	2.76
Jun 24	3.96
May 24	3.18
May 24	3.07
Apr 24	3.65
Mar 24	3.55
Mar 24	3.28
Mar 24	3.31
Mar 24	3.43
Jan 24	3.88
Jan 24	3.87
Jan 24	3.85
Jan 24	3.85

No video analysis for this stock yet. Request one from our team.

News: IPHYF

businesswire.com · 14 Aug 2026

Innate Pharma Announces Conference Call and Webcast

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.

businesswire.com · 10 Aug 2026

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding So.

businesswire.com · 10 Aug 2026

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLO.

businesswire.com · 21 Jul 2026

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose escalation of the Phase 1 study of IPH4502 (NCT06781983), its proprietary Nectin-4 exatecan ADC. Preliminary data are expected by year-end and will include data from 76 patients, guiding Phase 1 dose optimization in selected tumor types.